BlackRock Portfolio Management LLC filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 1,560,091 shares of Enanta Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported beneficially owning 1,560,091 shares of Enanta Pharmaceuticals Inc. common stock.
  • Percent of class: The reported position represents 5.4% of Enanta Pharmaceuticals Inc.'s outstanding common shares.
  • Sole voting power: The filing states sole voting power over 1,461,051 shares, with 0 shares subject to shared voting power.
  • Sole dispositive power: Sole power to dispose of or direct the disposition of all 1,560,091 shares is reported, with no shared dispositive power.
  • Event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Ordinary course certification: The filing certifies the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

BlackRock Portfolio Management LLC's Reported Position in Enanta Pharmaceuticals

According to the Schedule 13G filed October 27, 2026, BlackRock Portfolio Management LLC, organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, disclosed beneficial ownership of 1,560,091 shares of common stock of Enanta Pharmaceuticals Inc. (CUSIP 29251M106). The filing is tied to an event date of September 30, 2026, and was signed by Spencer Fleming, Managing Director, on behalf of BlackRock Portfolio Management LLC.

The filing states that BlackRock Portfolio Management LLC holds sole voting power over 1,461,051 shares and sole dispositive power over the full 1,560,091 shares. Shared voting and shared dispositive power are each reported as zero. The aggregate beneficial ownership of 1,560,091 shares represents 5.4% of the class, according to the filing.

The filing notes, in accordance with SEC Release No. 34-39538 (January 12, 1998), that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates" and does not include securities owned by other business units disaggregated from the Reporting Business Units. The filing further discloses that various persons have the right to receive dividends from, or proceeds from the sale of, the reported shares, but that no single person's interest exceeds five percent of total outstanding common shares.

What Was Disclosed

BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 1,560,091 shares, or 5.4%, of Enanta Pharmaceuticals Inc. common stock as of September 30, 2026, with sole voting power over 1,461,051 shares and sole dispositive power over all reported shares.